Immunohistochemical and molecular evaluation of TUSC2 expression in breast cancer
- PMID: 38446366
- DOI: 10.1007/s11033-024-09320-z
Immunohistochemical and molecular evaluation of TUSC2 expression in breast cancer
Abstract
Objective: Tumor suppressor candidate 2 has shown to be deleted in lung, colon, and bladder cancer types. In the present study, we aimed to investigate the expression of TUSC2 in breast cancer.
Materials and methods: A total of thirty patients with breast cancer were included in the study. Normal and tumor tissue samples from fresh mastectomy materials were stored at -80 C until the number of cases was completed for gene expression analysis. Histopathological examination was carried out with routine hematoxylin & eosin method. TUSC2 staining was performed for immunohistochemical analysis.
Results: The tumors of thirteen patients were Luminal A, fourteen patients were Luminal B, one patient was cerbB2(+), and tumors of two patients were triple-negative. Ki67 proliferation index was less than 14% in fifteen cases and tumor size was less than 2 cm in seven cases. Lymphovascular invasion and lymph node metastasis were present in thirteen cases. Statistically, TUSC2 expression significantly decreased or was lost in breast tumor tissues compared to normal tissues (p < 0.0001). TUSC2 expression decreased as the Ki67 proliferation index increased (p = 0.0003), and TUSC2 expression decreased as tumor size increased (p = 0.0483). The loss or decrease in the TUSC2 expression was significant as the tumor grade increased (p = 0.3740). Gene expression analysis correlated with immunohistochemistry results.
Conclusion: The results of the present study demonstrated a decrease or loss of TUSC2 expression in breast cancer tissue compared to normal tissue. A correlation was found between TUSC2 expression and Ki67 proliferation index and tumor size.
Keywords: Breast cancer; Tumor grade; Tumor size; Tumor suppressor candidate 2 expression.
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed
-
- Kawiak A (2022) Molecular Research and treatment of breast Cancer. Int J Mol Sci 23(17):9617. https://doi.org/10.3390/ijms23179617 - DOI - PubMed - PMC
-
- Kondo M, Ji L, Kamibayashi C, Tomizawa Y, Randle D, Sekido Y et al (2001) Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene 20(43):6258–6262. https://doi.org/10.1038/sj.onc.1204832 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical